Study
| Open-label, multicohort, phase II study (EV-202) |
| Recurrent/metastatic head and neck cancer previously treated with platinum-based chemotherapy and PD-1/PD-L1 inhibitors |
| Enfortumab vedotin 1.25 mg/kg IV on days 1, 8, and 15 of each 28-day cycle |
Efficacy
| ORR: 23.9% |
| DCR: 56.5% |
| mPFS: 3.9 mos |
| mOS: 6.0 mos |
| mDOR: 9.4 mos (at later data cutoff) |
Safety
| Grade ≥3 AEs: anemia (4.3%), decreased neutrophil count (4.3%) |
| Common AEs (any grade): alopecia (28.3%), fatigue (26.1%), peripheral sensory neuropathy (23.9%) |
| Treatment-related deaths: 4.3% |
J Clin Oncol 2024;43:578-88
http://doi.org/10.1200/JCO.24.00646
Reviewed by Ulas D. Bayraktar, MD on Mar 2, 2025
